Intended for healthcare professionals

Editorials

SGLT2 inhibitors and kidney outcomes in the real world

BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1584 (Published 29 April 2020) Cite this as: BMJ 2020;369:m1584

Linked Research

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events

Linked Analysis

Communicating emerging risks of SGLT2 inhibitors

  1. Steven M Smith, assistant professor of pharmacy
  1. Department of Pharmacotherapy and Translational Research and Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, PO Box 100486, Gainesville, 32610-0486, FL, USA
  1. ssmith{at}cop.ufl.edu

Observational data from clinical practice favour these drugs over DPP4 inhibitors

Chronic kidney disease affects 700 million individuals worldwide and contributes to one in 20 deaths annually.1 Globally, the age standardised mortality rate attributable to CKD has remained virtually unchanged over the past decade, in contrast to most other non-communicable chronic diseases for which these rates have fallen.12 This seemingly intractable problem is driven largely by diabetes.1 It is thus not surprising that sodium glucose cotransporter 2 (SGLT2) inhibitors have garnered considerable attention following recent clinical trials showing consistent benefits of these glucose lowering drugs on major adverse kidney outcomes.3456

Taken together, current evidence strongly suggests a role for SGLT2 inhibitors in people with or at risk of chronic kidney disease. Yet the key trials left important questions unanswered for clinicians and patients. All were placebo controlled and had highly …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription